Overview

Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

Status:
Completed
Trial end date:
2016-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well adolescent kidney transplant patients tolerate a single dose of belatacept they receive at least 6 months after transplant surgery, and how their body handles the drug.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept